MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Rifalazil

CAS No. : 129791-92-0

MCE 站：Rifalazil

产品活性：Rifalazil (ABI-1648; KRM-1648) 是利福霉素衍生物，可抑制细菌依赖 DNA 的 RNA 聚合酶 (RNA polymerase) 并阻断 RNA 聚合酶中的 β 亚基从而杀死细菌感染的细胞。Rifalazil (ABI-1648; KRM-1648) 是一种抗生素 (antibiotic)，对分枝杆菌，革兰氏阳性细菌，幽门螺杆菌，肺炎衣原体和沙眼衣原体有抑制作用，其 MIC 值在 0.00025 至 0.0025 μg/ml 之间。Rifalazil (ABI-1648; KRM-1648) 有潜力用于衣原体感染，梭菌相关性腹泻菌感染?(CDAD) 和结核病 (TB) 研究的相关研究。

研究领域：Cell Cycle/DNA Damage  |  Anti-infection

作用靶点：DNA/RNA Synthesis  |  Bacterial

In Vitro: Rifalazil exhibits antimicrobal activity against Gram-positive enteric bacteria, inhibits Clostridium difficile, Clostridium perfringens, Bacteroides fragilis with MIC₅₀ value of 0.0015, 0.0039, 0.0313 ?g/ml, respectively.
Rifalazil exhibits antimicrobal activity against Gram-negative enteric bacteria, inhibits Escherichia coli and Klebsiella pneumoniae with MIC₅₀ value of 16 and 16 ?g/ml, respectively.
Rifalazil exhibits antimicrobal activity against non-enteric Gram-positive bacteria, inhibits Methicillin-susceptible Staphylococcus aureus, Methicillin-resistant S. aureus, Methicillin- and quinolone-resistant S. aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae with MIC₅₀ value of 0.0078, 0.0078, 0.0078, 0.0078, 0.0002, 0.0001 ?g/ml, respectively.
Rifalazil exhibits antimicrobal activity against Helicobacter pylori, Chlamydia pneumoniae and Chlamydia trachomatis with MIC₅₀ value of 0.004, 0.000125 and 0.00025 ?g/ml, respectively.

In Vivo: Rifalazil (oral gavage; 20, 25, and 150 mg/kg; 6-8 weeks) combines with isoniazid (INH) for 6 weeks or greater significantly reduced the number of mice per group in which?M. tuberculosis?is detected in both spleens and lungs compared to the reductions for the early and late controls. And the addition of Pyrazinamide (PZA) does not significantly improve RLZ-INH therapy at any time point.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Immunology/Inflammation Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Macrocyclic Compound Library  |  Antibacterial Compound Library  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Puromycin dihydrochloride  |  Cycloheximide  |  Dexamethasone  |  Staurosporine  |  Remdesivir  |  Oxaliplatin  |  Gemcitabine  |  G-418 disulfate  |  Doxycycline (hyclate)  |  5-Azacytidine  |  Etoposide  |  Nigericin sodium salt  |  CCCP  |  Actinomycin D  |  Resveratrol  |  Mitomycin C  |  Hygromycin B  |  Bleomycin sulfate  |  Tunicamycin  |  Carboplatin  |  Tacrolimus  |  Ionomycin  |  Cytarabine  |  Methotrexate  |  Favipiravir  |  Vancomycin hydrochloride  |  Tanespimycin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。